Back to Journals

Journal of Inflammation Research

ISSN: 1178-7031

Professor Ning Quan

Professor Quan

Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA

Dr. Quan is a Professor at the Florida Atlantic University where he serves as a member of the Brain Institute and the Department of Biomedical Science in the College of Medicine. During his PhD thesis research, he demonstrated a hypothermic effect of norepinephrine in the preoptic area of the hypothalamus. As a postdoctoral fellow at Duke University, he demonstrated the existence of IL-1 bioactivity in normal brain, linking this inflammatory cytokine to physiological neural functions of the central nervous system (CNS). During his research fellowship at the National Institute of Mental Health, he demonstrated that the blood brain barrier can serve as a relay of neuroimmune communication, transmitting peripheral immune signal to the brain.

Dr. Quan's past research at the Ohio State University focused on understanding the communication pathways between the immune system and the CNS and the neural functions of the mediators of neuroimmune communication. He demonstrated a role for proinflammatory cytokines in mediating neurodegeneration induced by the chronic CNS infection of Trypanosoma brucei, described the temporospatial distribution of IL-1 and COX-2 expression after peripheral immune challenge, uncovered a location-specific neural pathway by which localized peripheral inflammation signals brain, discovered multiple promoters in the IL-1R1 gene that drives cell type specific expression of IL-1R1 in the CNS to mediate diverse functions of IL-1 in the brain, leading to the identification of IL-1R3.

His current research includes further dissecting the role of IL-1R1 and COX-2 in the brain by creating and analyzing mouse lines which express these molecules in specific cell types of the brain, elucidating mechanisms underlying a novel type of peripheral inflammation recently discovered in his lab-inflammation without the induction of sickness behaviors and neuroimmune activation, and exploring the potential clinical benefits of this type of inflammation.

At national and international levels, Dr. Quan has served as a member and chairman of multiple NIH study sections, a member of grant review panels for UK and Canada and on the editorial boards of multiple journals.

Dr Adam D Bachstetter

Dr Bachstetter

Department of Neuroscience, University of Kentucky, Lexington, KY, USA

Dr. Adam Bachstetter is an Associate Professor of Neuroscience at the University of Kentucky. His primary affiliation is with the Spinal Cord and Brain Research center at the University of Kentucky. He is also affiliated with the Sanders-Brown Center on Aging at the University of Kentucky.

Dr. Bachstetter completed his Ph.D. from the University of South Florida, where he described the function of the CX3CR1/CX3CL1, microglia/neuron communication, in age-related decreases in neuroplasticity and neurogenesis. He then completed a postdoctoral fellowship at Northwestern University on CNS drug discovery, where he contributed to the development of two brain-specific small molecule compounds designed to modify neuroinflammation. Following this he completed postdoctoral training at the University of Kentucky on signal transduction mechanisms regulating neuroinflammation. Dr. Bachstetter described the essential role of p38 MAPK in microglia-mediated neuroinflammation. He completed additional postdoctoral training in human neuropathology at the University of Kentucky, where he described the role of dystrophic microglia in Alzheimer's disease and related dementias.

Research in Dr. Bachstetter's laboratory is focused on therapeutic approaches to target neuroinflammation following traumatic brain injury or in Alzheimer's disease and related dementias. His research also focuses on the cellular process involved in microglia and astrocyte degeneration in neurodegenerative diseases and how the degeneration of the glia alters homeostatic neuron-glia interactions.

Prof. Dr. Subashchandrabose Chinnathambi

Prof. Dr. Chinnathambi

Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India

Subashchandrabose Chinnathambi obtained his PhD in Biochemistry from Max Planck Institute for Structural Molecular Biology (MPASMB), Hamburg, Germany in 2011. His postdoctoral training was completed at the German Centre for Neurodegeneration Disease (DZNE) Bonn and Max Planck Institute for Neurobiological Research Cologne, Germany. After a short postdoctoral stint he joined the Biochemical Sciences Division, National Chemical Laboratory (CSIR-NCL) as a Scientist Assistant Professor. 

Prof. Dr. Chinnathambi has examined the influence of phosphorylation on the pathological conformation of human microtubule associated protein Tau in Alzheimer’s disease. His scientific interests are the physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, Purinergic and Chemokine receptors, Tau stem cell, Animal models, Neuropharmacology, and Translational research. He has mainly worked with Tau protein folding and Tau oligomers internalization in microglial system. His group identified the phagocytosis of full length Tau oligomers by Actin-remodeling of activated microglia. Prof. Dr. Chinnathambi's research work has resulted in outstanding achievements with potential practical applications and publications in high-impact journals.

Prof. Dr. Chinnathambi is currently funded by various government agencies like Department of Biotechnology (DBT), Council of Scientific and Industrial Research, National Chemical Laboratory, and the Science and Education Research Board from Department of Science and Technology, Government of India. He has also worked with the National Institute of Mental Health and Neuroscience, Bangalore; Institute of National Importance (INI) funded by the Ministry of Health and Family Welfare, Government of India. Currently he is one of the Co-Principal Investigators and interested to study the blood-based biomarkers for Tauopathy in AD funded by National Institute of Aging (NIA) and National Institute of Health (NIH).

Over the years, his lab has produced a number of high quality graduate students and master interns. Prof. Dr. Chinnathambi has been awarded by CSIR-NSL research foundation the best Scientist of the year 2021, for outstanding research contribution to Tau protein in Alzheimer’s disease. He is supported by an EMBO travel grant, EuroTau 2023 travel grant and registration grant, is a DBT Neuroscience task force member, and has received many grants from Department of Biotechnology, and the Department of Science and technology from Government of India. He is part of the international grant review from Alzheimer's Society United Against Dementia, National Science Grant Belgium, National Grant France and Alzheimer’s Research UK.
Subash is part of the editorial board of various other international cell biology journals. He is also a regular invited speaker at various national and international meetings and workshops. With more than 16 years of research experience in the area of Neuroscience and Tau-related research in Alzheimer’s Disease.

Dr Monika Sharma

Dr Sharma

Biology, Gilead Sciences, Foster City, CA, USA

Dr. Monika Sharma is a Research Scientist at Gilead Sciences. Being a part of this organization, she thrives to contribute significantly to bring novel drug targets for fibrotic diseases by supporting and leading research efforts of critical programs in highly matrix environment of Gilead Sciences. Prior to this role, she was a postdoctoral fellow at New York University Langone Medical Center in Prof Kathryn Moore’s lab. She received American Heart Association Fellow during her research time at NYU.

After obtaining her Master’s degree from Panjab University, India, she moved to New Zealand where she received her PhD from the University of Otago under the supervision of Prof Sally McCormick. During her PhD training, she studied the metabolism and intracellular trafficking of lipoprotein(a). Her academic training and research experience have provided her with an excellent background in multiple biological disciplines including immunology, biochemistry, molecular biology, microbiology, and genetics. Along with two peer-reviewed publications, as a major part of her challenging PhD project, she discovered a novel receptor for lipoprotein(a). As the therapeutics to lower Lp(a) levels are still developing, the need for understanding the clearance mechanism holds a great promise for drug targets. Her work on finding the receptor for Lp(a) that leads to the degradation of a part of Lp(a) was published in Circulation Research, which made it to the cover image for that issue and also lead to an editorial in the same issue.

During her graduate studies in New Zealand, she received many scientific and non-scientific honors both in New Zealand as well as internationally. Her research work received a huge acclaim at the scientific community, which bolstered her confidence to move forward and learn new aspects in metabolic diseases and life-threatening diseases such as cancer. In her post-doctoral research training, she has built the multi-disciplinary aspects of chronic inflammatory disorders such as cardiovascular disease and metabolic disease. The major goal of her research is to identify mechanisms to reduce atherosclerotic cardiovascular disease. Her research has tested that regulatory T cells prevent stop the chronic inflammation and initiate tissue repair to shrink plaques. Dr. Sharma's studies are in progress to identify new therapeutic targets to promote atherosclerosis regression, in line with the American Heart Association's 2020 goal of improving cardiovascular diseases by 20%. Her study was published in Circulation Research in 2020 which was also accompanied by "News & Highlights section" in Nature Reviews Cardiology. Her other work of netrin-1, a molecule has proven to be an inflammatory molecule in various disease states such as atherosclerosis. Her study published in Immunometabolism have suggested that netrin-1 deletion from macrophages, may prevent the weight gain and its consequences of metabolic disorders. She has contributed as co-author is several publications. Monika's full list of Publications can be found here.

Dr Tara Strutt

Dr Strutt

Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA

Dr. Tara M. Strutt is an Assistant Professor within the Immunity and Pathogenesis Division of the Burnett School of Biomedical Sciences in the College of Medicine at the University of Central Florida (UCF) in Orlando, FL, USA. She is an affiliate member of the UCF NanoScience Technology Center. She earned her Ph.D. in Immunology from the University of Saskatchewan in Canada studying naïve CD4 T cell activation. Her postdoctoral studies at the Trudeau Institute in NY explored the protective functions of CD4 T memory cells during recall responses towards respiratory viral infection with influenza A virus. She joined the Faculty at the University of Massachusetts Medical School in MA as an Instructor in 2010 and transitioned to an Assistant Professor prior to joining UCF in 2015.

Dr. Strutt's research program studies how memory CD4+ T cells, such as those induced by vaccination, function to regulate inflammatory responses and mediate protection. She is leveraging this knowledge in pre-clinical models to improve the outcomes of infection in expectant mothers, an at-risk group for severe influenza infection, with the use of universally protective vaccines. Her research program is also developing a novel therapeutic intervention that has the potential to temper overzealous inflammatory responses in the lung during infection with a broad range of pathogens.

Editorial Board

Salomon Amar, Provost for Biomedical Research/Chief Biomedical Research Officer, Touro College and University System; Professor of Pharmacology, Professor of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA

Haydee E.P. Bazan, Professor, Department of Ophthalmology, LSU Health Science Center, New Orleans, LA, USA

J. Edwin Blalock, Professor, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

Senior Scientist, AbbVie Inc. Baiyi Cai, Pathology Department, School of Medicine, University of Alabama at Birmingham, AL, USA

K. K. Dharmappa, Associate Professor and Chairperson, DOSR in Biochemistry, Mangalore University, Jnana Cauvery Campus, Chikka Aluvara, India

Vinay Kumar, Research Scientist, Researcher, Pennsylvania State University Hershey Medical Center, Hershey, PA, USA

Ramesh J Kurukulaaratchy, Associate Professor & (Hon) Consultant in Respiratory Medicine and Allergy, Clinical Experimental Sciences, Southampton General Hospital, Southampton, UK

Dr Xiaoyu Liu, Scientist, Multiple Sclerosis Research Department, Biogen, Cambridge, MA, USA

Longfei Pan, Associate Professor and Associate Chief Physician, Emergency Department / EICU, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China

Sachchida Nand Rai, Postdoctoral Researcher, Centre of Experimental Medicine and Surgery (CEMS), Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Ajagara, Varanasi, Uttar Pradesh, India

Sinisa Savic, Associate Professor, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK

Concetta Schiano, Assistant Professor, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania, Caserta, Italy

Manish Kumar Singh, Assistant Staff Scientist, Arthritis & Clinical Immunology (ACI), Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

Gary A. Weisman, Professor, Department of Biochemistry, University of Missouri-Columbia, Columbia, MO, USA

Zili You, Professor, University of Electronic Science and Technology of China, Chengdu, Sichuan, China